ESNM-ESO Learning Course on 18FDG PET-CT in Lymphoma

Chairs: L. Ceriani, CH - S. Stroobants, BE


As a joint initiative, the European School of Nuclear Medicine and the European School of Oncology are pleased to announce the first edition of the ESNM/ESO course on 18FDG PET/CT in lymphoma.
There is a growing demand for academic education for oncologists/haematologists and nuclear physicians to increase their competence in interpreting PET-CT findings and using these data in the staging and treatment process. The recent publication of the consensus paper of the International Conference on Malignant Lymphomas - Imaging Working Group about the role of imaging together with the updated staging classification of malignant lymphomas (Lugano Classification, JCO 2014) confirmed the pivotal role of 18FDG PET-CT in the management of the lymphoproliferative diseases. Furthermore, the need to apply standard specific criteria to assure the best use of hybrid imaging in clinical studies as well as in clinical practice will be discussed.
The course is designed as a forum for oncologists/haematologists and nuclear physicians who seek to expand their knowledge and competence in interpreting PET-CT findings and using these data in staging and treating lymphoma patients.


TARGET GROUP
The course is open to nuclear physicians, oncologists/haematologists and other specialists who seek training in the use of PET-CT imaging in the evaluation of patients with lymphomas, whether for daily practice or in a clinical research setting.
To guarantee high interactivity, attendance will be limited to 20 participants.


MAIN TOPICS
• Analysis of PET-CT data
• Image interpretation and description
• Classification
• Reporting and integration in the response assessment as well as practical sections covering
• Hodgkin lymphoma
• Diffuse large B-cell lymphoma
• Follicular lymphoma
• Primary mediastinal lymphoma


LEARNING OBJECTIVES
After the course the participants should:
• Improve interpretation skills in the evaluation of 18FDG PET-CT scans in patients with different types of lymphomas
• Learn how to implement the novel Lugano Classification for staging and response assessment
• Understand how to translate information into a nuclear medicine report that is clinically relevant
Learning objectives for each lecture are available HERE

An initiative of

 

ORGANISING SECRETARIAT
European School of Nuclear Medicine (ESNM)
Schmalzhofgasse 26
1060 Vienna, AUSTRIA
Tel: +43 (0) 1 890 44 27
eMail: a.falkner@eanm.org
eMail: esnm@eanm.org


VENUE
European School of Nuclear Medicine (ESNM)
Schmalzhofgasse 26
1060 Vienna
Austria

FACULTY (as of August 2015)
A. Biggi, Azienda Ospedaliera Sante Croce e Carle Cuneo, Cuneo, IT
L. Ceriani, Oncology Institute of Southern Switzerland, Bellinzona, CH
M. Hutchings, Rigshospitalet, Copenhagen University Hospital, DK
P. Johnson, University of Southampton, Southampton General Hospital, Southampton, UK
M. Meignan, Hopital Henri Mondor, Creteil, FR
S. Stroobants, University Hospital Antwerp, Edegem, BE
J. Zijlstra, Amsterdam, NL
E. Zucca, Oncology Institute of Southern Switzerland, Bellinzona, CH

15 April

13:00		Welcome address and introduction of the instructors Concept and goals of the course
13:15		MCQs
14:00 - 14:30 Theoretical session 1 Malignant Lymphoma: classification and introduction P. Johnson, UK
14:30 - 16:30 Theoretical session 2 Role of PET-CT in initial staging and treatment evaluation in Lymphomas
14:30		Hodgkin Lymphoma A. Biggi, IT
15:00		DLBCL S. Stroobants, BE
15:30		Follicular Lymphoma J. Zijlstra, NL
16:00		PMBCL E. Zucca, CH
16:30		Coffee Break
16:45 - 17:45 Theoretical session 3 How to interpret PET-CT findings in Lymphomas
16:45		From IHP criteria to The Deauville 5-points scale M. Meignan, FR
17:15		The Lugano classification M. Hutchings, DK
17:45 - 18:15 Theoretical session 4 How to report PET-CT in lymphomas L. Ceriani, CH
18:15		Reflection and Discussion
19:30		Dinner Meeting point: 19:00 in the lobby of Hotel City Central

 

16 April

8:30		Presentation on handling of the workstations and how to read the studies
8:50		Form 4 groups of max. 5 people
9:00 - 16:15 Practical sessions 1-4 running in parallel (1,5 h per group/topic/workstation)
		Practical session 1 HL A. Biggi, IT
		Practical session 2 DLBCL M. Meignan, FR
		Practical session 3 FL S. Stroobants, BE
		Practical session 4 PMBCL L. Ceriani, CH
10:30		Coffee Break
12:15		Lunch Break
14:30		Coffee Break
16:15		Tumour Board with discussion of the clinical cases reported autonomously by the 4 groups
17:45		MCQs & Evaluation
18:30		End of the course